Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma

Journal of Otolaryngology - Head and Neck Surgery

Volumn 44, Issue 1, 2015, Pages

  Cooper, Timothy ^a   Biron, Vincent L ^a   Fast, David ^b   Tam, Raymond ^c   Carey, Thomas ^d   Shmulevitz, Maya ^b   Seikaly, Hadi ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Head and neck cancer; HPV; Reovirus; Squamous cell carcinoma

Indexed keywords

ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ALAMAR BLUE VIABILITY ASSAY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; DRUG MECHANISM; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REOVIRIDAE; REOVIRUS INFECTION; SQUAMOUS CELL CARCINOMA CELL LINE; UM SCC 104 CELL LINE; UM SCC 47 CELL LINE; VIRUS INFECTIVITY; WART VIRUS; CARCINOMA, SQUAMOUS CELL; CELL DEATH; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAMMALIAN ORTHOREOVIRUS 3; OTORHINOLARYNGOLOGIC NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; CELL DEATH; HUMAN PAPILLOMAVIRUS 16; HUMANS; MAMMALIAN ORTHOREOVIRUS 3; ONCOLYTIC VIROTHERAPY; OTORHINOLARYNGOLOGIC NEOPLASMS; PAPILLOMAVIRUS INFECTIONS;

EID: 84942598654     PISSN: 19160216     EISSN: None     Source Type: Journal    
DOI: 10.1186/s40463-015-0062-x     Document Type: Article

References (49)

1. Rutten H, Pop LA, Janssens GO, Takes RP, Knuijt S, Rooijakkers AF, et al. Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: Results of a multidisciplinary late morbidity clinic. Int J Radiat Oncol, Biol, Phys. 2011;81(4):923-9.
2. Lau HY, Brar S, Klimowicz AC, Petrillo SK, Hao D, Brockton NT, et al. Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy. Head Neck. 2011;33(2):251-6.
3. Laco J, Nekvindova J, Novakova V, Celakovsky P, Dolezalova H, Tucek L, et al. Biologic importance and prognostic significance of selected clinicopathological parameters in patients with oral and oropharyngeal squamous cell carcinoma, with emphasis on smoking, protein p16(INK4a) expression, and HPV status. Neoplasma. 2012;59(4):398-408.
4. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261-9.
5. Cooper T, Biron V, Adam B, Klimowicz AC, Puttagunta L, Seikaly H. Prognostic utility of basaloid differentiation in oropharyngeal cancer. J Otolaryngol Head Neck Surg. 2013;42:57. 0216-42-57.
6. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35.
7. Bossi P, Orlandi E, Miceli R, Perrone F, Guzzo M, Mariani L, et al. Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: A tertiary cancer centre series analysis. Ann Oncol. 2014;25(3):694-9.
8. Cardesa A, Nadal A. Carcinoma of the head and neck in the HPV era. Acta Dermatovenerol Alp Panonica Adriat. 2011;20(3):161-73.
9. El-Mofty SK, Patil S. Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: Characterization of a distinct phenotype. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(3):339-45.
10. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709-20.
11. Nichols AC, Faquin WC, Westra WH, Mroz EA, Begum S, Clark JR, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2009;140(2):228-34.
12. El-Mofty SK, Lu DW. Prevalence of human papillomavirus type 16 DNA in squamous cell carcinoma of the palatine tonsil, and not the oral cavity, in young patients: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol. 2003;27(11):1463-70.
13. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated ras pathway. Science. 1998;282(5392):1332-4.
14. Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol. 1978;28(2):444-9.
15. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol. 1977;54(4):307-15.
16. Maitra R, Ghalib MH, Goel S. Reovirus: a targeted therapeutic-progress and potential. Mol Cancer Res. 2012;10(12):1514-25.
17. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol. 1996;70(1):612-6.
18. Strong JE, Tang D, Lee PW. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology. 1993;197(1):405-11.
19. Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ. Oncolytic reovirus type 3 (dearing) as a novel therapy in head and neck cancer. Expert Opin Biol Ther. 2012;12(12):1669-78.
20. Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther. 2008;15(18):1257-70.
21. Etoh T, Himeno Y, Matsumoto T, Aramaki M, Kawano K, Nishizono A, et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res. 2003;9(3):1218-23.
22. Ikeda Y, Nishimura G, Yanoma S, Kubota A, Furukawa M, Tsukuda M. Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx. 2004;31(4):407-12.
23. Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2002;13(5):641-52.
24. Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, et al. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther. 2013;20(5):521-8.
25. Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, et al. Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer. 2012;12:368. 2407-12-368.
26. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res. 2008;14(3):912-23.
27. Shmulevitz M, Marcato P, Lee PW. Unshackling the links between reovirus oncolysis, ras signaling, translational control and cancer. Oncogene. 2005;24(52):7720-8.
28. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther. 2007;15(8):1522-30.
29. Pan D, Pan LZ, Hill R, Marcato P, Shmulevitz M, Vassilev LT, et al. Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-kappaB activation. Br J Cancer. 2011;105(7):1012-22.
30. Shmulevitz M, Lee PW. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture. Methods Mol Biol. 2012;797:163-76.
31. Shmulevitz M, Marcato P, Lee PW. Activated ras signaling significantly enhances reovirus replication and spread. Cancer Gene Ther. 2010;17(1):69-70.
32. Shmulevitz M, Pan LZ, Garant K, Pan D, Lee PW. Oncogenic ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res. 2010;70(12):4912-21.
33. Pan D, Marcato P, Ahn DG, Gujar S, Pan LZ, Shmulevitz M, et al. Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis. PLoS One. 2013;8(1):e54006.
34. Black AJ, Morris DG. Clinical trials involving the oncolytic virus, reovirus: ready for prime time? Expert Rev Clin Pharmacol. 2012;5(5):517-20.
35. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012;18(7):2080-9.
36. Brookes JT, Seikaly H, Lim T, Wong KK, Harris JR, Moore RB. Reovirus salvage of squamous cell cancer-contaminated wounds. J Otolaryngol. 2005;34(1):32-7.
37. Mechor B, Seikaly H, Wong K, Chau J, Uwiera R, Harris JR. Reovirus salvage of positive resection margin: a novel treatment adjunct. J Otolaryngol. 2006;35(2):97-101.
38. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res. 2011;17(23):7248-64.
39. Tang AL, Hauff SJ, Owen JH, Graham MP, Czerwinski MJ, Park JJ, et al. UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head Neck. 2012;34(10):1480-91.
40. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck. 2010;32(4):417-26.
41. Mendez II, Hermann LL, Hazelton PR, Coombs KM. A comparative analysis of freon substitutes in the purification of reovirus and calicivirus. J Virol Methods. 2000;90(1):59-67.
42. Rampersad SN. Multiple applications of alamar blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel). 2012;12(9):12347-60.
43. Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol, Biol, Phys. 2011;81(4):915-22.
44. Mirghani H, Amen F, Moreau F, Guigay J, Hartl DM, Lacau St Guily J. Oropharyngeal cancers: Relationship between epidermal growth factor receptor alterations and human papillomavirus status. Eur J Cancer. 2014;50(6):1100-11.
45. Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol. 2013;14(8):e302-9.
46. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res. 1992;52(21):5997-6000.
47. Tang AL, Hauff SJ, Owen JH. UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoman cell line. Head Neck. 2012;34(10):1480-91.
48. Biron VL, Mohamed A, Hendzel MJ, Alan Underhill D, Seikaly H. Epigenetic differences between human papillomavirus-positive and -negative oropharyngeal squamous cell carcinomas. J Otolaryngol Head Neck Surg. 2012;41 Suppl 1:S65-70.
49. Barber BR, Biron VL, Klimowicz AC, Puttagunta L, Cote DW, Seikaly H. Molecular predictors of locoregional and distant metastases in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2013;42:53. 0216-42-53.